



GILUPI participates in Consortium “European Liquid Biopsies Academy” - ELBA

Blood of cancer patients contains different types of cancer-derived materials that are susceptible to detailed analysis of tumor disease: intact circulating tumor cells (CTCs), cell-free circulating tumor DNA, tumor educated platelets and extracellular vesicles. Different techniques can isolate those biomarkers and are used as diagnostic and monitoring tools for cancer treatment. These blood-based tests (also called liquid biopsy) are a sensitive and less invasive alternative or complementary approach to tissue biopsies.

The research program and educational curriculum of the European Liquid Biopsy Academy - ELBA^[1], a MSCA ITN funded project (GA 765492), educates 15 early stage researchers in a range of applications and disease areas surrounding liquid biopsy. For this purpose, different companies perform trainings on state-of-the-art technologies and tools, diagnostic test development and further topics. As part of the educational program, GILUPI, together with other companies has successfully organized the first training workshop for liquid biopsy. During this training the students got familiar with the GILUPI CellCollector[®] for the isolation of CTCs and were trained in using this innovative technology to analyze CTCs.

Christian Jurinke, CEO of GILUPI commented: We are proud to participate in this educational workshop and to support the ELBA organization in their goal to promote innovative medical and diagnostic applications in an international and cooperative setting.

^[1] <http://elba.uni-plovdiv.bg/>

About GILUPI GmbH

GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the *in vivo* isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.

Individual oncological targeted therapies become increasingly important in personalized medicine. The identification of the right drug for the individual patient is today's challenge in clinical practice. To address this medical need, the GILUPI CellCollector[®] is used to enrich rare cells by immunocapture directly in the patient's bloodstream. This methodology has proven to yield highest cell numbers and patient positivity rates in various cancer types. Applying diagnostic analyses ranging from immunostaining, DNA- and RNA-based methods, isolated cells can be characterized and/or analyzed down to a molecular level.

The GILUPI CellCollector[®] is the first *in vivo* CTC isolation product worldwide that is CE approved.

For further information visit www.gilupi.com